Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysis - PubMed
2 hours ago
- #hepatocellular carcinoma
- #immunotherapy
- #tyrosine kinase inhibitor
- Study investigates efficacy of second-line tyrosine-kinase inhibitors (TKIs) after first-line immunotherapy in advanced hepatocellular carcinoma (HCC).
- Meta-analysis included 16 studies (1663 patients) with TKIs like Sorafenib, Lenvatinib, Regorafenib, and Cabozantinib, mostly after atezolizumab-bevacizumab first-line therapy.
- Median overall survival for all patients was 9.8 months; Lenvatinib and Regorafenib showed significantly longer 12-month OS compared to Sorafenib.
- Median progression-free survival was 3.2 months; Lenvatinib and Regorafenib had significantly better 6-month PFS than Sorafenib.
- Findings are exploratory due to observational data limitations; prospective studies are needed to define optimal post-immunotherapy sequencing.